KR101166739B1 - 약학 조성물 - Google Patents

약학 조성물 Download PDF

Info

Publication number
KR101166739B1
KR101166739B1 KR1020097026736A KR20097026736A KR101166739B1 KR 101166739 B1 KR101166739 B1 KR 101166739B1 KR 1020097026736 A KR1020097026736 A KR 1020097026736A KR 20097026736 A KR20097026736 A KR 20097026736A KR 101166739 B1 KR101166739 B1 KR 101166739B1
Authority
KR
South Korea
Prior art keywords
pharmaceutical composition
compound
alkyl
hydroxy
compounds
Prior art date
Application number
KR1020097026736A
Other languages
English (en)
Korean (ko)
Other versions
KR20100065126A (ko
Inventor
야스히로 하라다
준이치 가와사키
다다시 하야시
류지 우에노
Original Assignee
수캄포 아게
가부시키가이샤 아루떼꾸 우에노
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 수캄포 아게, 가부시키가이샤 아루떼꾸 우에노 filed Critical 수캄포 아게
Publication of KR20100065126A publication Critical patent/KR20100065126A/ko
Application granted granted Critical
Publication of KR101166739B1 publication Critical patent/KR101166739B1/ko

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Ophthalmology & Optometry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medical Preparation Storing Or Oral Administration Devices (AREA)
KR1020097026736A 2008-10-07 2009-10-02 약학 조성물 KR101166739B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US10340308P 2008-10-07 2008-10-07
US61/103,403 2008-10-07
PCT/JP2009/067586 WO2010041722A2 (en) 2008-10-07 2009-10-02 Pharmaceutical composition

Publications (2)

Publication Number Publication Date
KR20100065126A KR20100065126A (ko) 2010-06-15
KR101166739B1 true KR101166739B1 (ko) 2012-07-23

Family

ID=41479177

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020097026736A KR101166739B1 (ko) 2008-10-07 2009-10-02 약학 조성물

Country Status (11)

Country Link
US (1) US20100087540A1 (es)
EP (1) EP2341894B1 (es)
JP (2) JP5320388B2 (es)
KR (1) KR101166739B1 (es)
CN (1) CN102215817B (es)
AR (1) AR073781A1 (es)
CA (1) CA2739710A1 (es)
ES (1) ES2392221T3 (es)
HK (2) HK1159501A1 (es)
TW (1) TWI403324B (es)
WO (1) WO2010041722A2 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8952051B2 (en) * 2009-11-05 2015-02-10 Allergan, Inc. Ophthalmic formulations containing substituted gamma lactams and methods for use thereof
JP5878128B2 (ja) * 2010-04-12 2016-03-08 株式会社アールテック・ウエノ 網膜疾患を処置するための方法および眼科用組成物
WO2014159679A1 (en) 2013-03-12 2014-10-02 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Methods for using lubiprostone to absorb fluid from the subretinal space

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020002185A1 (en) 1997-03-17 2002-01-03 Reed Kenneth Warren Compositions and methods for reducing ocular hypertension
US20040076678A1 (en) * 2002-08-21 2004-04-22 Sucampo Ag Opthalmic solution

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69105349T2 (de) * 1990-05-22 1995-04-06 R Tech Ueno Ltd Behandlung von intraocularem Druck mit einer synergistischen Kombination zur ophthalmischen Verwendung.
BR9906597A (pt) * 1998-07-14 2000-07-18 Alcon Lab Inc Produto de prostaglandina
AU2002212234A1 (en) * 2000-09-14 2002-03-26 Novartis Ag Stable ophthalmic preparation
EP2404606A1 (en) * 2003-08-21 2012-01-11 Sucampo AG Ophthalmic compositions comprising a prostaglandin and a viscosity agent
US20050049311A1 (en) * 2003-09-03 2005-03-03 Pharmacia & Upjohn Company Medicinal products comprising prostaglandin compositions and methods of packaging such compositions
BRPI0414149A (pt) * 2003-09-05 2006-10-31 Novartis Ag composições compreendendo derivados de benzo(g)-quinolina e derivados de prostaglandina
US20050287325A1 (en) * 2004-06-25 2005-12-29 Pharmacia & Upjohn Company Pharmaceutical containers with low adsorption/absorption of active ingredients, and a method of testing materials for adsorption/absorption of active ingredients
GB0501192D0 (en) * 2005-01-20 2005-03-02 Resolution Chemicals Ltd Stable prostaglandin-containing compositions
KR101382922B1 (ko) * 2006-03-13 2014-04-08 가부시키가이샤 아루떼꾸 우에노 수성 조성물
WO2008096804A1 (ja) * 2007-02-07 2008-08-14 Teika Pharmaceutical Co., Ltd. ラタノプロスト含有点眼剤
CN101959500A (zh) * 2008-03-17 2011-01-26 爱尔康研究有限公司 包含硼酸类化合物-多元醇络合物的水性药物组合物

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020002185A1 (en) 1997-03-17 2002-01-03 Reed Kenneth Warren Compositions and methods for reducing ocular hypertension
US20040076678A1 (en) * 2002-08-21 2004-04-22 Sucampo Ag Opthalmic solution

Also Published As

Publication number Publication date
TWI403324B (zh) 2013-08-01
JP2011509237A (ja) 2011-03-24
HK1162935A1 (en) 2012-09-07
KR20100065126A (ko) 2010-06-15
TW201016219A (en) 2010-05-01
WO2010041722A3 (en) 2011-01-27
CN102215817A (zh) 2011-10-12
EP2341894B1 (en) 2012-08-29
HK1159501A1 (en) 2012-08-03
US20100087540A1 (en) 2010-04-08
JP5320388B2 (ja) 2013-10-23
ES2392221T3 (es) 2012-12-05
JP2013177446A (ja) 2013-09-09
AR073781A1 (es) 2010-12-01
EP2341894A2 (en) 2011-07-13
WO2010041722A2 (en) 2010-04-15
CA2739710A1 (en) 2010-04-15
CN102215817B (zh) 2013-06-12

Similar Documents

Publication Publication Date Title
JP6084942B2 (ja) 水性組成物
JPH0640919A (ja) 高眼圧症あるいは緑内障の治療剤
JP5686819B2 (ja) 黄斑浮腫を処置するための医薬組成物
JP2013100330A (ja) 眼科用組成物
US20120263803A1 (en) Aqueous ophthalmic composition
KR101166739B1 (ko) 약학 조성물
AU2010237744A1 (en) Method and composition for treating macular degeneration
KR100681221B1 (ko) 문맥압 상승 억제제
KR20040008174A (ko) 고안압증 및 녹내장 치료방법
WO2004071514A1 (en) 15-keto-prostaglandin derivatives for treating ocular hypertension and glaucoma

Legal Events

Date Code Title Description
A201 Request for examination
E902 Notification of reason for refusal
E701 Decision to grant or registration of patent right
GRNT Written decision to grant
FPAY Annual fee payment

Payment date: 20150604

Year of fee payment: 4

FPAY Annual fee payment

Payment date: 20160523

Year of fee payment: 5

LAPS Lapse due to unpaid annual fee